Lifestyle intervention and/or statins for the reduction of C‐reactive protein in type 2 diabetes: From the look AHEAD study |
| |
| Authors: | L. Maria Belalcazar Steven M. Haffner Wei Lang Ron C. Hoogeveen Julia Rushing Dawn C. Schwenke Russell P. Tracy F. Xavier Pi‐Sunyer Andrea M. Kriska |
| |
| Affiliation: | 1. Department of Medicine, University of Texas Medical Branch, Galveston, Texas, USA;2. Department of Medicine, University of Texas Health Science Center, San Antonio (Retired), Texas, USA;3. Department of Biostatistical Sciences, Wake Forest University School of Medicine, Winston‐Salem, North Carolina, USA;4. Department of Medicine, Baylor College of Medicine, Houston, Texas, USA;5. College of Nursing and Health Innovation, Arizona State University, Phoenix, Arizona, USA;6. Department of Pathology, University of Vermont, Burlington, Vermont, USA;7. Department of Medicine, Columbia University, St. Luke's–Roosevelt Hospital, New York, New York, USA;8. Department of Epidemiology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA |
| |
| Abstract: | Objective: Cardiovascular risk remains high despite statin use. Overweight/obese diabetic persons usually have normal/low LDL‐cholesterol but high C‐reactive protein (CRP) levels. We aimed to examine the effects of intensive lifestyle intervention for weight loss (ILI) on CRP levels in overweight/obese diabetic individuals by statin use. Design and Methods: Look AHEAD was a randomized trial in overweight/obese type 2 diabetic individuals testing whether ILI would reduce cardiovascular mortality, when compared to usual care. CRP changes in 1,431 participants with biomarker levels, who remained on or off statin treatment for 1 year, were evaluated. Results: The reduction in CRP levels with ILI at 1 year in men and women on statins was ?44.9 and ?42.3%, respectively, compared to ?13.7 and ?21.0% for those on statins and usual care (P < 0.0001). At 1 year, median CRP levels were: 1.8 mg L?1 in participants randomized to ILI on statin therapy; 2.6 mg L?1 for those on statins randomized to usual care and 2.9 mg L?1 for participants not on statins but randomized to ILI. Weight loss was associated with 1‐year CRP reduction (P < 0.0001) in statin and nonstatin users. Conclusions: Our findings suggest that in overweight/obese diabetic persons, ILI and statin therapy may have substantial additive anti‐inflammatory benefits. |
| |
| Keywords: | |
|
|
